NorthWest Biotherapeutics Inc (NWBO)

[MI Dendream]

There will be nothing produced by this silly investigation into Aduhelm. Simply, FDA has more faith in Biogen than any other company because of how they handled everything related to Tysabri ideally, including building the strongest risk map that balanced patient desire with patient and physician security. Then they continued to make it safer, but demand did not slip, so it was a Blockbuster until something slightly safer with similar efficacy came out.

They both knew of this safety risk which is why they restricted the study and it’s use to patients with a low beta-amyloid burden. The drug is designed to help the immune system remove amyloid plaques. They hoped the commercial market would follow this guidance, but alas it did not. Now patients with too much amyloid burden are have issues with a robust immune response in the one organ that has no space to expand. It is literally the only organ completely encased bone. It does not do well with inflammation.

I could have just saved the taxpayers a whole lot of money, but not only does my opinion have no weight but Congress loves a good smokescreen so that they can ignore the tough work that would lead to being voted out if an ignorant constituency listenes to lying biased pundants which news media calls news but is unfounded opinion from both sides most of the time.